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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Receptor antagonists that block the binding
of chemokines such as CXCL8 (IL-8) are
effective in animals models of
neutrophil-mediated inflammation.
• It has been hypothesized that selective
inhibition of neutrophil trafficking and
activation may be a useful adjunct for the
treatment of inflammatory airway diseases
such as chronic obstructive pulmonary
disease or cystic fibrosis. A CXCR1/2 receptor
antagonist has shown activity in an ozone
challenge model in humans.
WHAT THIS STUDY ADDS
• SB-656933, a selective CXCR2 antagonist, is
safe and well-tolerated at single doses and
is shown to inhibit agonist
(CXCL1)-mediated expression of the CD11b
on peripheral blood neutrophils as well as
ozone-induced airway neutrophilia in
healthy subjects.
AIMS
To determine the safety and tolerability of a novel selective CXCR2 antagonist
and assess its pharmacodynamic effects using measures of neutrophil activation
and function, including CD11b expression in whole blood and ozone-induced
airway inflammation in healthy subjects.
METHODS
Flow cytometric determination of ex vivo CXCL1-induced CD11b expression on
peripheral blood neutrophils was performed following single dose oral
administration of SB-656933 (dose range 2–1100 mg). A subsequent randomized
study (placebo, 50 mg and 150 mg) was performed to explore the dose–
response for ozone-induced airway inflammation, as measured by sputum
biomarkers.
RESULTS
Oral administration of SB-656933 resulted in significant inhibition of
CXCL1-induced CD11b expression on peripheral blood neutrophils at single
doses greater than or equal to 50 mg. Maximum inhibition (70%) relative to
placebo was observed following administration of SB-656933 400 mg (95% CI
60%, 77%). This was sustained up to a dose of 1100 mg. Single doses of
SB-656933 reduced ozone-induced airway inflammation in a dose-dependent
manner. Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95%
CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose
of 50 mg or 150 mg, respectively. There was a corresponding reduction in
myeloperoxidase concentrations in the sputum supernatant of 32.8% (95% CI
9.2, 50.3) and 50.5% (95% CI 33.3, 63.3). SB-656933 was safe and well-tolerated
at all doses.
CONCLUSIONS
SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on
neutrophil activation and recruitment within a well-tolerated dose range. These
data suggest that SB-656933 may be an effective agent in neutrophil-
predominant diseases.
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Introduction
Neutrophils are key effector cells in a number of acute and
chronic respiratory diseases including chronic obstructive
pulmonary disease (COPD), cystic fibrosis (CF), acute lung
injury and bronchiolitis obliterans syndrome [1, 2]. During
a normal immune response, neutrophils are the first hae-
matopoietic cells that migrate into inflamed or infected
tissues, in order to eliminate invading micro-organisms
(e.g. viruses and bacteria). In response to chemokine
signals generated by resident cells at the site of injury,
neutrophils up-regulate expression of the cell surface inte-
grin CD11b that subsequently binds to the adhesion mol-
ecule ICAM-1 on endothelial cells, enabling neutrophil
transmigration through the endothelial cell lining into the
underlying parenchyma [3]. Recruitment of neutrophils to
sites of inflammation, if followed by inadequate removal of
them from the injured site, results in the subsequent and
persistent release of a number of inflammatory mediators
and proteinases from neutrophils, including neutrophil
elastase and matrix metalloproteinases that contribute to
the progressive fibrosis, airway stenosis and destruction of
the lung parenchyma.
The chemokine receptor CXCR2 is a member of the G
protein-coupled receptor superfamily and is expressed
on the surface of neutrophils in mammals [4]. In humans,
CXCR2 mediates neutrophil chemotaxis in response to
tissue injury and many types of infections (reviewed in [5]).
However, there are also pathways for neutrophil recruit-
ment that are CXCR2-independent [6]. CXCR2 chemokine
ligands, such as CXCL8 (IL-8) or CXCL5 (ENA-78), are
elevated in bronchoalveolar lavage (BAL) fluid and sputum
of COPD and CF patients [7, 8]. Other peptides, such as
PGPa and LL-37, have also been shown to bind CXCR2 on
neutrophils [9, 10] and may act as chemoattractants. Selec-
tive antagonism of the interaction between CXCR2 and its
various ligands therefore provides a potential strategy for
impacting neutrophil chemotaxis to sites of airway injury
and hence reduces the underlying inflammation that con-
tributes to the progression of COPD and other respiratory
diseases [11]. In preclinical studies, administration of a
selective CXCR2 antagonist was shown to inhibit CXCL1-
induced neutrophil chemotaxis in vitro and LPS-induced
airway neutrophilia in vivo [12]. Recent clinical studies have
demonstrated that a potent antagonist of both CXCR1 and
CXCR2 inhibits ozone-induced airway neutrophilia [13, 14].
SB-656933 is a novel, selective, competitive and revers-
ible CXCR2 antagonist in development for the treatment
of CF and COPD [15]. In preclinical studies, the compound
was shown to inhibit CXCL1-induced CD11b up-regulation
on PMNs in an in vitro whole blood assay and to be active
in in vivo rodent inhalation challenge models of airway
inflammation that used endotoxin and ozone to induce
airway neutrophilia [16, 17]. This same assay (with minor
modifications for a clinical setting) demonstrated that the
compound inhibited neutrophil CD11b up-regulation in
whole blood cells from patients with COPD [18], suggest-
ing that the assay might be a useful adjunct for monitoring
neutrophil activation in disease and may facilitate clinical
dose selection for studies in patients.
In this report, we describe the results of two studies
with SB-656933 designed to test the hypothesis that
the CD11b pharmacodynamic assay provides a means to
monitor the potential effects of SB-656933 on parameters
of acute lung inflammation. These studies assessed the
safety, pharmacokinetics and pharmacodynamics of single
escalating doses of SB-656933 in healthy subjects dur-
ing basal conditions (FTIH), as well as examined proof
of mechanism (PoM) of CXCR2-selective antagonism on
airway inflammation in healthy humans using an inhala-
tion challenge model of ozone-induced airway inflamma-
tion. In particular, the CD11b data collected from the FTIH
study were used to select the doses that were tested in the
PoM study. Together, the two studies provide a compre-
hensive overview of the pharmacodynamics of SB-656933,
using both whole blood CD11b expression and ozone
challenge, and can be used to support dose selection for
clinical efficacy studies.
Methods
First time in humans (FTIH) study
(GSK Protocol CR2100595)
The FTIH study was designed as a randomized, single blind,
placebo controlled dose escalation study and was con-
ducted at a single centre in the United Kingdom between
June–September 2004. Two cohorts consisting of a total
of 20 healthy non-smoking male subjects between the
ages of 18 and 50 years were randomized to receive single,
escalating oral doses of SB-656933. Subjects in cohort
1 received doses of 2–150 mg and subjects in cohort
2 received doses of 150–1100 mg [2 mg (n = 10), 10 mg
(n = 10), 50 mg (n = 10), 150 mg (n = 20), 400 mg (n = 10),
800 mg (n = 10), 1100 mg (n = 10)], as well as placebo
(n = 18). A third cohort consisting of 12 healthy non-
smoking male subjects between the ages of 18 and 50
years was randomized to receive placebo, 150 mg and
1100 mg SB-656933 in a three-way crossover study,
designed to provide more comprehensive pharmacody-
namic data.
Ozone challenge study (GSK Protocol
CR2100597; NCT00551811)
The ozone challenge study was a randomized, double-
blind,placebo controlled three-way crossover trial that was
conducted at a single centre in Germany between October
2007 and July 2008.Subjects were required to have an FEV1
of 80% predicted and a documented response to ozone
(>10 percentage point increase from baseline) in sputum
neutrophils [19]. Twenty-four healthy non-smoking male
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subjects were randomized to receive a single dose of
50 mg, 150 mg or placebo 1 h prior to ozone challenge.
Subjects were exposed to 250 ppb ozone over a 3 h
period in each of the challenge sessions (Figure 1). During
exposure, subjects alternated between 15 min of light
exercise on a bicycle ergometer and 15 min of rest. The
minute ventilation (VE) was measured during the last
2 min of each exercise period and exercise intensity
adjusted to maintain the target minute ventilation of
approximately 12.5 l min-1m-2 BSA (~25 l min-1). The dose
of ozone and design of the ozone-exercise challenge
selected for this study was based on previous studies dem-
onstrating poor response at ozone exposures below 200
ppb, adequate response at 250–270 ppb and maximum
responses at 400 ppb [19–23]. This protocol has been
shown to induce reproducible mild transient neutrophilic
airway inflammation that resolves back to pre-exposure
levels by 24 h [20]. Induced sputum was collected at 6 h
following the initiation of ozone challenge [24]. The
sputum neutrophil response following ozone exposure for
the two active treatment periods was compared with the
response following placebo.
Sputum induction and processing
Sputum induction and processing were performed as
previously described [24]. Differential cell counts were
performed on 400 non-squamous cells by two indepen-
dent readers. Sputum supernatant was analyzed for total
protein content (Pierce) and myeloperoxidase (MPO)
(Immunodiagnostik) by ELISA [24–26], according to the
manufacturer’s instructions. Dithiothreitol was used as a
reducing agent in the processing of the sputum samples
but previous validation experiments have shown it to have
negligible impact on the fluid phase components mea-
sured in this report. Results of the MPO assay were normal-
ized to total protein in the sputum supernatant. Serum
Clara cell protein-16 (CC-16) was analyzed by ELISA,accord-
ing to the manufacturer’s instructions (BioVendor).
Flow cytometric analysis of CD11b expression
on neutrophils
CXCL1-induced CD11b expression on peripheral blood
neutrophils was determined using a whole blood assay as
previously described [18] with minor modifications for
a clinical site setting at varying times post-dosing. Briefly,
whole blood was incubated at 37°C for 10 min with either
CXCl-1 or buffer. The samples were placed on ice and ice-
cold fixative added. After 1 min, an aliquot was removed
and incubated with CD11b FITC (Beckman Coulter) and
CD16 PE (Dako). A control sample containing mouse IgG2a
FITC (Beckman Coulter) and CD16 was also prepared. The
tubes were gently mixed and left on ice in the dark for
20 min.After staining with antibody, the sample was added
to cold DPBS (0.5 ml) containing LDS-751 solution (Cam-
bridge Bioscience). The samples were mixed again and
kept on ice in the dark for 10 min prior to analysis by flow
cytometry (FACSCalibur, BD Biosciences).
Safety
Safety was monitored by the measurement of ECG, vital
signs and assessment of adverse events (AEs). In addition,
blood was collected for haematology and clinical chemis-
try determinations. In the ozone challenge study, pulmo-
nary function tests (FVC, PEFR, FEV1) were collected at
baseline and hourly between 0–8 h following the initiation
of the ozone challenge.
Ethics
The study protocol, any amendments, the informed
consent, and other information that required pre-approval
were reviewed and approved by a national, regional or
investigational centre ethics committee. Each study was
conducted in accordance with good clinical practice (GCP)
and all regulatory requirements, including, where appli-
cable, those originating from the Declaration of Helsinki.
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Figure 1
Study design for the single dose human healthy volunteer ozone challenge
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Dose selection for FTIH and ozone challenge
The pharmacokinetics (PK) of SB-656933 in humans were
predicted by allometric scaling (data not shown). This
information, combined with preclinical pharmacology and
safety, informed the FTIH doses which reflected the expo-
sure range between minimal anticipated biologically effec-
tive level (MABEL) and maximal no observed adverse effect
level (NOAEL). On this basis a 2 mg dose was selected as
the starting dose.
The dose selection for the single dose ozone challenge
was made on the basis of safety, PK and PD data obtained
from the FTIH study. CXCL1-induced CD11b inhibition data
collected in the FTIH study were subject to population
PK/PD modelling. Doses of 50 and 150 mg were subse-
quently selected to achieve CD11b expression levels cor-




Blood samples for the determination of SB-656933 plasma
concentrations were taken in the FTIH study at pre-dose
and at the nominal times of 10 min and 0.5, 1, 2, 3, 4, 6, 8, 12,
18, 24, 32, 48 and 72 h post-dose. Samples were collected
into tubes containing EDTA and immediately chilled on
crushed ice. Plasma was separated by centrifugation at
approximately 4°C, at 1500 g for 10 min and transferred
to polypropylene specimen containers. Plasma specimens
were immediately frozen and stored at approximately
-70°C (or colder). Plasma samples were analyzed for
SB-656933 by GSK using a validated analytical method
based on protein precipitation, followed by HPLC/MS/MS
analysis. For the initial 2 mg dose group, 50 ml aliquots of
EDTA human plasma were used. The lower limit of quanti-
fication (LLQ) for SB-656933 was 1 ng ml-1 and the upper
limit of quantification (HLQ) was 1000 ng ml-1. For subse-
quent dose groups, the same method with a higher quan-
tification range (10–10 000 ng ml-1) and 25 ml aliquots of
EDTA human plasma was used.
Pharmacokinetic assessment of individual plasma
SB-656933 concentration–time profiles was conducted
by non-compartment analysis using the Model 200 (for
extravascular administration) of WinNonlin Professional
(Pharsight Corporation, Mountain View, CA).Actual elapsed
time from dosing was used to estimate all individual
plasma PK parameters. The maximum observed plasma
concentration (Cmax) and the first time to reach Cmax (tmax),
were the actual observed values. The terminal plasma
elimination rate constant (lz) was estimated from log-
linear regression analysis of the terminal phase of the
plasma concentration–time profile. The associated appar-
ent terminal elimination half-life (t1/2) was calculated as
t1/2 = ln2/lz.The area under the plasma concentration–time
curve from time zero extrapolated to infinity [AUC(0,•)]
was calculated by the linear up/logarithmic down trap-
ezoidal method. The apparent oral clearance (CL/F) was
calculated as Dose/AUC(0,•). PK parameters were summa-
rized by dose using descriptive statistics.
PK/PD analysis
Population PK/PD analysis of the FTIH study was per-
formed using non-linear mixed effects modelling utilizing
NONMEM V on a PC-based platform. A two-step sequential
PK/PD methodology was employed.First, a compartmental
pharmacokinetic model was fitted to the PK data in order
to estimate concentrations for each subject at the time
points of CD11b measurements. Second, a physiological,
competitive inhibition pharmacodynamic model was
fitted to the ex vivo stimulated whole blood CD11b expres-
sion data, accounting for relationship between stimulating

















where CD11b is the absolute CD11b expression, E0 is the
baseline or unstimulated level of CD11b expression, ligand
is the concentration of CXCL, Cp is the plasma concen-
tration of SB-656933, Emax is the maximum stimulated
CD11b expression, Km is concentration of CXCL1 required
to achieve half the maximum stimulated CD11b expres-
sion, KI is the inhibition constant for the inhibition of
stimulated CD11b expression by SB-656933, M is the
hill coefficient for CXCL1 concentration and N is the Hill
coefficient for SB-656933 concentration.
Statistical analysis
For the FTIH study, the sample size was primarily based on
balancing the need to obtain adequate safety data and
logistical considerations, although the following statistical
considerations were applied. It was planned that data from
overlapping doses in cohorts I and II would be pooled
resulting in a maximum of 32 subjects on the overlapping
dose and would give at least 90% power to detect an
inhibition of 50%, or more, on neutrophil CD11b surface
expression. The lowest dose level in cohort II matched the
highest dose level in cohort I.
For the ozone study, the planned sample size arose pri-
marily from logistic feasibility and not statistical consider-
ations. Estimates of the within subject variation for total
sputum neutrophil count following challenge with inhaled
ozone and intermittent exercise in healthy volunteers, rela-
tive to placebo were based on the data of Alexis et al. [25].
Based on the estimate of a within subject standard devia-
tion of 0.65,with a sample size of 24 subjects, the lower and
upper bounds of the 95% confidence interval for the total
neutrophil count active vs. placebo was calculated to be
46.9% of the point estimate.
The primary endpoint, total number of neutrophils in
induced sputum post-ozone challenge, was analyzed fol-
lowing a natural logarithmic transformation using a mixed
SB-656933 inhibits ozone-induced airway inflammation
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effects model, with period and treatment fitted as fixed
effects and subject as a random effect. The suitability of
the transformation was assessed by examining the model
residuals. Treatment effects were evaluated in terms of
treatment ratios and were calculated as the anti-log for the
differences between the LS means and 95% confidence
intervals were determined using pooled estimates of vari-
ance for the LS means difference and then anti-logged.
A similar mixed effects model was fitted for the untrans-
formed percent neutrophils/ml post-ozone challenge.
Adjusted means for each treatment group were calculated,
along with corresponding 95% confidence intervals. The
differences between each SB-656933 dose and placebo
were calculated along with the corresponding 95% confi-
dence intervals of these differences. Similar calculations
were made for the analysis of total leucocytes, macroph-
ages, lymphocytes and eosinophils.
The concentration of inflammatory mediators in
sputum (ratio of MPO : total protein) and serum (CC-16)
was analyzed following a loge transformation using a
similar mixed effects model. The suitability of transforma-
tion of the data was assessed by examining the model
residuals. Assumptions of normality and homoscedasticity
were examined using residual plots. Where necessary, an
appropriate transformation of the response variable was
be used and the analysis was performed on the trans-
formed scale.
The mean fluorescence signal for CD11b surface
expression on neutrophils following exposure to the
30 nM CXCL1 was adjusted to baseline levels to account for
variation in sampling processing and assay sensitivity. The
adjusted endpoint was analyzed following a loge transfor-
mation. Subject and period baselines, period, treatment,
time, baseline by time and treatment ¥ time interactions
were fitted as fixed effects, with subject as a random effect
and time as a repeated effect. Adjusted geometric means
for each treatment and ratios in adjusted geometric means
for comparisons of each dose vs. placebo were deter-
mined. Assumptions of normality and homoscedasticity
were examined using residual plots.
Results
Subject disposition
Thirty-two subjects entered the FTIH study and received at
least one dose of study medication.Two subjects withdrew
from the study, one due to a protocol violation (failed
drugs of abuse screen) and the other because he was
unable to attend the second study session.
One hundred forty-eight subjects were screened to
enrol 24 in the ozone challenge study. There was a high
screen failure rate due to either inability to produce
sputum or non-responsiveness to ozone. All subjects com-
pleted all assessments and there were no withdrawals.
The demographics and baseline characteristics for
these subjects are shown in Table 1.
Pharmacokinetics
Plasma pharmacokinetic concentration–time profiles over
96 h for single doses 2–1100 mg are shown in Figure 2.
Following ascending dose administration, systemic expo-
sure to SB-656933 increased with dose.The concentration–
time profiles depicted an apparent multi-exponential
decline following the peak, with concentrations of
SB-656933 measurable at all time points in the majority
of subjects for each treatment (i.e. median values for
SB-656933 were above the lower limit of quantitation
(LLQ) up to 72 h), with the exception of 2 mg, where
median concentrations were above the LLQ only up to 32h.
The time to maximum concentration (tmax) was
between 2–3 h for all doses ranging from 2 mg–1100 mg.
Based on visual inspection of within-individual data




Mean (range) Mean (range)
Age (years) 25.6 (19, 38) 35.5 (27–50)
Sex (M/F) 32/0 24/0
Race (White/Asian/Other) 30/1/1 22/0/2
Height (cm) 178.4 (168, 190) 179.9 (169, 194)
Weight (kg) 76.3 (56, 95) 84.7 (66.2, 104.8)
BMI (kg m-2) 23.9 (18.9, 28.7) 26.1 (21.3, 29.8)
FEV1 (l) 4.2 (1.9, 5.5) 4.51 (3.63, 6.26)
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Figure 2
SB-656933 concentration–time profiles after administration of single
doses in human healthy volunteers. 933 2 mg (); 933 10 mg (-------);
933 50 mg (); 933 150 mg (); 933 400 mg (); 933 800 mg ();
933 1100 mg ()
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and area under curve (AUC(0,•)) appeared dose propor-
tional following single doses up to 400 mg, with less than
dose proportional increases at higher doses. The t1/2 was
approximately 14–20 h,and with the exception of the 2 mg
data where low, variable exposure combined with assay
limitations likely contributed to estimation of a shorter
median apparent t1/2, t1/2 appeared independent of dose.
These empirical observations suggested some absorption
limitations of SB-6565933 with the tested formulation as
the dose increased.
CD11b surface expression on neutrophils
Human peripheral blood neutrophils express both CXCR1
and CXCR2 [27]. In order to assess neutrophil function
in response to dose escalation of a CXCR2 antagonist,
we measured CD11b expression induced by the CXCR2-
specific ligand, CXCL1. Baseline expression of CD11b was
low in all subjects; stimulation of cells with 30 nM CXCL1
resulted in an approximate three-fold induction in CD11b
expression on neutrophils (data not shown). The dose–
response for agonist-induced CD11b following dosing
with SB-656933 is demonstrated in Figure 4. The plot
shows the ratio of peak mean fluorescent signal (MFS) rep-
resenting CXCL1-induced CD11b expression on neutro-
phils relative to placebo over a period of 0–9 h. A dose-
dependent inhibition of CD11b was observed at doses up
to 400 mg, at which point a maximum level of inhibition
of approximately 70% (95% CI 60%, 77%) was achieved
and sustained up to the dose level of 1100 mg.
The time course of inhibition of CD11b expression by
SB-656933 is illustrated in Figure 5. For doses between
50 mg and 1100 mg, the level of CXCL1-induced CD11b
expression declined between 0–6 h following dosing.
An extended pharmacodynamic profile over 48 h was
obtained in subjects receiving doses of 150 mg and
1100 mg, demonstrating sustained inhibition of CD11b
expression for at least 24 h compared with placebo.
PK/PD analysis
PK and CD11b expression data from all 32 subjects were
included in the population PK/PD analysis. The model give
a reasonable fit to the observed data and population PD
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Figure 4
Peak CD11b expression (measured as mean fluorescence signal, MSF
0–9 h) relative to placebo adjusted for unstimulated control (95% CI),on
peripheral blood neutrophils following stimulation of whole blood with
30 nM CXCL1
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(SEM <50% for all parameters). Based on pre-clinical rodent
models of acute lung inflammation, a target range of
50–70% inhibition of CXCL1-induced CD11b expression
was established, which corresponded to reductions in
airway neutrophils of up to 75% relative to controls.
Maximum inhibition of CD11b expression was not
required to achieve maximal reductions in neutrophils in
these models. Mean CD11b response in the ozone chal-
lenge study was predicted by simulation using the PK/PD
model developed in the FTIH study. Based on these simu-
lations, 50 mg and 150 mg were predicted to achieve peak
population predicted CD11b expression inhibition close to
50–70% range established pre-clinically (Figure 6). For the
150 mg dose, inhibition was predicted to be maintained
above the lower 50% range for the entire duration of the
ozone challenge.
Reduction in ozone-induced airway
inflammation
Sputum neutrophils Having demonstrated that SB-
656933 was active in an ex vivo assay, we then tested
whether SB-656933 would be active in an in vivo ozone
challenge model. Following ozone challenge, the adjusted
geometric mean total number of neutrophils in induced
sputum from subjects who received placebo was 74 (95%
CI: 45.8, 118.8) ¥ 104 cells ml-1 (Figure 7). The increase in
sputum neutrophils following ozone challenge in patients
receiving placebo was similar to that seen at baseline
ozone screening and suggests that the subjects remained
ozone responsive (data not shown).
For subjects receiving single doses of SB-656933 50 mg
and 150 mg, the mean total numbers of neutrophils were
reduced to 33 ¥ 104 cells ml-1 (95% CI 19.3, 55.7) and 19 ¥
104 cells ml-1 (95% CI 11.6, 31.8), respectively. Relative to
placebo, estimates adjusted for period indicated that on
average there were 55% (P = 0.0084) fewer neutrophils
in the sputum of subjects after a single 50 mg dose of
SB-656933 and 74% (P < 0.0001) fewer neutrophils in
the sputum of subjects after a single 150 mg dose of
SB-656933, 7 h post-dose. The corresponding reduction in
CXCL1-induced CD11b expression on peripheral blood
neutrophils 5 h post-dose was 42.8% (P = 0.0119) and
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The period adjusted geometric mean for the change in CD11b expression
(MSF) relative to control (30 nM–0 nM CXCL1) on peripheral blood neutro-
phils over time by treatment. Plocebo (); 933 2 mg (-------); 933 10 mg
(); 933 50 mg (); 933 150 mg (); 933 400 mg (); 933 800 mg ();








































Time course of population predicted CXCl-1 induced CD11b inhibition,
expressed as % baseline, for 30 nM concentration of CXCL1, simulated for
proposed doses 50 mg (-------) and 150 mg (—) SB-656933 in the single
dose ozone challenge study, overlaid with the target pharmacological


















































The adjusted geometric mean (95% CI) for leucocyte counts in sputum
following ozone challenge. Plocobo (); 933 50 mg (+); 933 150 mg ()
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Similarly, the mean percentage of neutrophils in
induced sputum following ozone challenge was 60.44%
for subjects receiving placebo (Table 3). For subjects
receiving single doses of SB-656933 50 mg and 150 mg,
the mean percentage of neutrophils was 42.3% and 36.3%,
respectively. This represents a difference of 18.10% (P <
0.0001) and 24.09% (P < 0.0001), compared with placebo.
Other sputum leucocytes The mean total number of leu-
cocytes in induced sputum from subjects who received
placebo was 109.5 ¥ 104 cells ml-1 (95% CI 79.5, 150.7)
(Figure 7). For subjects receiving single doses of SB-656933
50 mg and 150 mg, the mean total number of leucocytes
was 77.1 ¥ 104 cells ml-1 (95% CI 54.0, 110.0) and 59.8 ¥ 104
cells ml-1 (95% CI 42.0, 85.0), respectively. There was a
trend for a reduction in total leucocytes ml-1 following a
single dose of SB-656933 50 mg, though this did not
reach statistical significance. In contrast, a single dose of
SB-656933 150 mg reduced sputum leucocytes by approxi-
mately 45% compared with placebo (P = 0.0022) (Table 3).
There was no difference in macrophage numbers
between the active treatments and placebo (Figure 7).
Conversely, analysis of the percent macrophages following
ozone challenge demonstrated an increase in levels for
both active treatments (SB-656933 50 mg and 150 mg)
relative to placebo. Estimates indicated that on average
there was a 15.6% increase relative to placebo (P = 0.0003)
in the percentage of macrophages in the sputum of sub-
jects following a single dose of SB-656933 50 mg and a
20.8% increase (P < 0.0001) in subjects receiving 150 mg
(Table 3). There were no significant differences in the
number or percent of eosinophils or lymphocytes in the
sputum of subjects receiving active treatment compared
with placebo.
Myeloperoxidase Following ozone challenge, there was a
significant decrease in the levels of sputum MPO following
single doses of both SB-65693 50 mg and 150 mg. Relative
to placebo, there was a 32.8% reduction in the sputum of
subjects dosed with SB-656933 50 mg (P = 0.0109) and a
50.5% reduction in subjects dosed with SB-656933 150 mg
(P < 0.0001) (Figure 8). In contrast, while ozone challenge
significantly increased the expression of the airway-
derived serum biomarker CC-16 in all groups, there was no
effect on serum concentrations following single doses of
SB-656933 (data not shown).
Safety
For the FTIH study, SB-656933 was generally well tolerated
when administered as a single dose (2–1100 mg) and the
proportion of subjects with adverse events (AEs) was
similar across all dose groups. All AEs were considered mild
to moderate and no subjects discontinued because of AEs.
Table 2
Change from control of CXCL1-induced expression of CD11b on periph-
eral blood neutrophils following ozone challenge
Treatment group
Adjusted geometric
mean CD11b (30 nM




Placebo 252.087 (186.742, 340.297)
SB-656933 50 mg 144.076 (102.843, 201.840) 42.8 (12.1, 62.9)
SB-656933 150 mg 109.710 (79.439, 151.516) 56.5 (34.0, 71.3)
CD11b MFS (30 nM CXCL1) has been adjusted for isotype and 0 nM CXCL1. MFS,
mean fluorescent signal.
Table 3







Placebo 60.44 (52.21, 68.67) –
SB-656933 50 mg 42.34 (33.53, 51.15) -18.10 (-26.23, -9.98)
SB-656933 150 mg 36.35 (27.81, 44.89) -24.09 (-31.51, -16.68)
Macrophages (%)
Placebo 36.96 (29.22, 44.70) –
SB-656933 50 mg 52.59 (44.27, 60.92) 15.63 (7.76, 23.51)
SB-656933 150 mg 57.75 (49.70, 65.81) 20.80 (13.60, 28.00)
Lymphocytes (%)
Placebo 1.20 (0.70, 1.71) –
SB-656933 50 mg 1.31 (0.75, 1.87) 0.11 (-0.52, 0.73)
SB-656933 150 mg 1.71 (1.17, 2.25) 0.50 (-0.08, 1.08)
Eosinophils (%)
Placebo 0.30 (-0.70, 1.31) –
SB-656933 50 mg 0.65 (-0.45, 1.74) 0.34 (-0.80, 1.48)























The adjusted geometric mean (95% CI) for myeloperoxidase (MPO) in
sputum supernatant following ozone challenge
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The most frequently experienced AE was headache,
reported in one subject each on placebo, 50 mg, 150 mg
and 400 mg SB-656933. Three subjects receiving
SB-656933 1100 mg reported headache.
For the ozone challenge study, SB-656933 was well
tolerated and the numbers of clinical AEs reported across
the three treatment sequences were similar. The most
frequently experienced AE in all treatment sequences
was headache, reported in four subjects on placebo and
150 mg SB-656933 and in six subjects receiving 50 mg
SB-656933.
One subject was diagnosed with Type 1 diabetes mel-
litus following completion of the ozone challenge study;
this event was reported as an SAE. Examination of blood
samples taken at screening revealed the presence of anti-
bodies against islet cells and glutamate decarboxylase.
Given these results, the investigator deemed the diabetes
mellitus as being unrelated to study medication.
A transient reduction in blood neutrophils was noted in
some subjects dosed with 400 mg SB-656933 (Figure 9).
The maximum effect was a mean reduction of approxi-
mately 50% observed 12 h following dosing, which was
when the first sample was taken. Neutrophil counts recov-
ered fully without additional treatment at 48 h after dosing
in the 400 mg dose group and by 72 h in the 800 mg and
1100 mg groups. In the ozone study, four subjects were
noted to have a neutrophil count below 2.05 GI l-1 after
receiving a single dose of SB-656933 150 mg, though no
subject was neutropenic. All counts returned to the normal
range on repeat testing.
Discussion
A challenge in the design of clinical trials is the need to
demonstrate proof of mechanism in humans within an
acceptable dose range, thereby selecting the most suitable
compounds for further development.The clinical doses for
SB-656933 were selected by linking inhibition of agonist-
induced CD11b expression on peripheral blood cells to
inhibition of airway neutrophilia in pre-clinical species, and
thus demonstrating an acceptable therapeutic index. The
CD11b assay was also implemented in the single dose
escalation study in healthy subjects presented here, similar
to the approach used in the testing of other chemokine
antagonists [28, 29]. SB-656933 was then assessed in an
ozone challenge model, where single doses of SB-656933
resulted in a dose-dependent inhibition of ozone-induced
airways neutrophilia at a magnitude predicted by the ex
vivo CD11b data. These results demonstrate how bridging
between pre-clinical species and humans is critical for
simplifying early clinical development of novel therapies.
The PK/PD modelling of the FTIH data effectively
informed dose selection of the ozone-challenge study
with confidence. The advantage of using a model-based
PK/PD analysis,particularly using a mechanistic population
approach to assess CD11b expression, was that all data
were combined and integrated in the model, providing a
more robust and certain interpolation and extrapolation
across the dose range rather than using the raw data in
isolation. This was especially useful with the type of cross-
over study conducted for the FTIH study, where the same
subjects received different treatments on multiple occa-
sions, and where pharmacodynamic measurements at low
doses were variable. One limitation of the ozone challenge
study was that pharmacokinetic parameters could not be
determined by population analysis due to limited sam-
pling, thus precluding assessment of a definitive PK–PD
relationship.
In both studies, SB-656933 was well-tolerated. The
observed fall in neutrophil counts after the higher doses
of SB-656933 in the FTIH study must be assumed to be
caused by the drug until proven otherwise, because of (i)
the relationship with size of dose and (ii) the time course
of recovery after dosing. The reduction in neutrophils is
unlikely to have been due to bone marrow suppression.
Although mature neutrophils are not long-lived, they are
not so evanescent that cessation of production would
cause their circulating numbers to fall by 50% within 12 h
of drug administration. A more likely explanation is that
SB-656933 caused a shift in distribution of neutrophils
from the circulating pool to the marginated pool. Signifi-
cant and more prolonged reductions in peripheral blood
neutrophils had been seen with other CXCR1/CXCR2
antagonists [13, 30] with activity in the ozone challenge
model. Initially, it was not clear whether this reduction in
blood neutrophils was necessary or contributed to the
pharmacological effect. Our own data demonstrating
a reduction in blood neutrophils at doses of 400 mg
and above, led us towards investigating lower doses of
SB-656933 in the ozone challenge study. In addition, the
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Median (IQR) peripheral blood neutrophil counts over time in the FTIH
study over the dose range 2–1100 mg of SB-656933. IQR: interquartile
range. Plocebo (); 933 2 mg (-------); 933 10 mg (); 933 50 mg ();
933 150 mg (); 933 400 mg (); 933 800 mg (); 933 1100 mg (+)
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would be sufficient to achieve the target pharmacology
range informed by rodent models. The results of the
current study clearly demonstrate that a reduction in
peripheral blood neutrophils is not a requirement for
inhibiting airway neutrophilia under challenge conditions
for this mechanism.
A reduction in neutrophil recruitment and activation
has several potential benefits in COPD and cystic fibrosis.
Neutrophil secretory products such as elastases and matrix
metalloproteinases are hypothesized to destroy lung
tissue and promote mucus hypersecretion. In addition,
elastase-mediated cleavage of CXCR1 is one proposed
mechanism for the reduced bacteriocidal capacity of neu-
trophils in patients with CF [31].However, neutrophil serine
proteases such as cathepsin G and neutrophil elastase are
also required to kill phagocytosed bacteria and fungi [32,
33].Since patients with COPD have decreased macrophage
phagocytic capacity, the ability to clear apoptotic neutro-
phils is reduced promoting a resting burden of neutrophils
in the airways and neutrophil-mediated tissue damage
[34]. Reduced neutrophil recruitment with CXCR2 therapy
therefore, may allow macrophage phagocytic function to
keep pace with the neutrophil burden in the airways of
patients with COPD and CF. Recent data suggest that
CXCR2 also mediates the formation of neutrophil extracel-
lular traps (NETs), DNA fibres coated with antimicrobial
proteins that serve an important function in host defense
[35]. Excessive deposition of NETs in the airway of patients
with cystic fibrosis correlated with poorer lung function. In
a murine model of cystic fibrosis, treatment with a CXCR2
antagonist decreased NET formation and improved lung
function [35].
SB-656933 may represent a novel therapeutic option
for patients with cystic fibrosis or other neutrophil-
predominant inflammatory respiratory diseases such as
COPD. The key challenge for this mechanism will be the
balance between inhibiting pro-inflammatory neutrophil
functions and maintaining host defense effector functions,
particularly in patients who may be chronically colonized
with bacteria. Previous neutrophil inhibitors have failed in
clinical trials in cystic fibrosis due to an increased risk of
pneumonia and exacerbation [36]. Recent studies with a
CXCR1/R2 antagonist have demonstrated almost com-
plete inhibition of ozone-induced neutrophilia [13] and a
significant reduction in airway neutrophils in patients with
neutrophilic asthma [37] and COPD [38]. It has yet to
be determined whether inhibition of neutrophilia in a
challenge model such as ozone will translate into clinical
benefits for patients with COPD or CF, or other neutro-
phil-predominant lung diseases. Encouraging data on ACQ
scores have been obtained in severe asthma [37].
In summary, these studies demonstrate that the selec-
tive CXCR2 antagonist SB-656933 inhibits agonist-induced
up-regulation of CD11b on peripheral blood neutrophils,
an effect that correlates with inhibition of ozone-induced
neutrophilia, at doses that are safe and well-tolerated.
Large scale studies are needed to determine whether inhi-
bition of neutrophilic inflammation will impact on long
term outcomes in CF or COPD.
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